Arena Sees Phase III Path For Etrasimod After Atopic Dermatitis Miss
Analysts Agreed The S1P Receptor Modulator Should Advance
Executive Summary
Arena said its S1P receptor modulator missed the primary endpoint in a Phase IIb trial but data from patients with uninterrupted treatment justify moving etrasimod into a pivotal program.